Sling Money Launches US and European Virtual Accounts in Partnership with Bridge to Expand Global Earning Power
AMSTERDAM--(BUSINESS WIRE)--May 22, 2025--
Sling Money, the app making global money movement instant and low-cost, today launched US and European Virtual Accounts, marking an expansion beyond peer-to-peer transactions to enable users to receive payments for freelance, project-based, or salaried work with ease. These accounts are provisioned by Bridge, a regulated financial infrastructure provider recently acquired by Stripe for $1.1 billion.
Sling Money users around the world can now access a US account and routing number or a European IBAN, meaning they can get paid like a local in both USD and EUR, directly into their Sling Wallet. USD accounts leverage ACH and wire rails, while EUR accounts operate over SEPA — including SEPA Credit and SEPA Instant — to ensure fast, reliable deposits.
Bridge automatically converts incoming payments into USDP (Pax Dollar) or EURC (Euro Coin) and transfers them into the user's Sling Wallet. From there, users can choose to hold incoming payments as stablecoins within the app, withdraw them as stablecoins — including USDC, USDP, and EURC — or convert them into local currencies for a negligible fee via Sling Money's extensive network of instant payment partners.
This feature unlocks a new level of utility for freelancers, remote workers, global nomads, creators, students studying abroad, and cross-border families who previously relied on slow, fee-laden intermediaries to receive international payments. With Virtual Accounts, users can now receive wages, payouts, reimbursements, or transfers natively.
'This is one of the first times a consumer wallet has made it possible for users worldwide to receive payments from the US and Europe using local account details, instantly tokenize those funds into stablecoins, and then move or spend that money globally — all within a single app,' said Mike Hudack, co-founder and CEO of Avian Labs, Sling Money's parent company. 'Sending money is only half the equation for an inclusive global financial system. Now, we're making it just as easy to get paid.'
The access to both real-time, low-fee transfers and Virtual Accounts makes Sling Money a complete solution for modern global earners. For senders, paying into a Sling Money account feels just like making a regular deposit.
Since its launch, Sling Money has expanded its global footprint across the U.S., Europe, Africa, and beyond, enabling users to send, receive, and convert funds in seconds using stablecoin technology and fiat integration. Recently, Sling Money also secured its Markets in Crypto Assets Regulation (MiCA) license and introduced EURC (Circle's euro-backed stablecoin), a testament to its compliance and growth in Europe.
About Sling Money
Sling Money is building a world where sending and receiving money is effortless. The app leverages stablecoin and real-time payment technology to allow people to move money anywhere, in any currency, nearly instantly and for a negligible fee. Sling Money makes global transfers easy by enabling users to pay people, not anonymous account numbers. It's available in 145+ countries on the Android and iOS app stores. An Avian Labs product, Sling Money was founded by Mike Hudack and Simon Amor, who have decades of product engineering and design experience. Learn more at www.sling.money.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250522678554/en/
CONTACT: Media Contact
Sasha Temerte,[email protected]
KEYWORD: EUROPE UNITED STATES NETHERLANDS NORTH AMERICA
INDUSTRY KEYWORD: SOFTWARE BANKING MOBILE/WIRELESS INTERNET PROFESSIONAL SERVICES BLOCKCHAIN FINTECH PAYMENTS APPS/APPLICATIONS TECHNOLOGY CRYPTOCURRENCY FINANCE
SOURCE: Sling Money
Copyright Business Wire 2025.
PUB: 05/22/2025 08:16 AM/DISC: 05/22/2025 08:16 AM
http://www.businesswire.com/news/home/20250522678554/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
18 minutes ago
- Forbes
Slack Down: Monday Morning Blues For Productivity App
Users are struggling to use Slack this morning Slack is investigating problems that are preventing some people from loading content in the corporate communications app this morning. DownDetector is reporting a sharp spike in Slack problems as Europe logs on for work on Monday morning. DownDetector shows a sharp increase in Slack outages Slack's own Status page has also acknowledged issues with the service. 'Some users may be experiencing issues loading content in Slack, particularly threads and the Activity view,' it reported at 07:25 BST. 'We're on the case and we'll be back with an update in 30 minutes.' A subsequent update added: "The work on this issue has been ongoing, but we've increased its urgency. "No additional news to share just yet, but we're focused on getting things back to normal as quickly as we can. We apologize for the continued trouble. 'We'll provide updates every 30 minutes until the impact is resolved for all users.' The problem certainly doesn't appear to be affecting all users. The service was operating normally in my brief tests this morning, suggesting it might only be affecting customers in certain regions. This is a breaking news story, more to follow.
Yahoo
24 minutes ago
- Yahoo
Bladder Cancer Drug Market Forecast and Analysis Report 2025: Focus on US, France, Germany, Italy, Spain, UK, Japan, and China - Epidemiology, Pipeline Therapies, 10 Year Forecasts
Explore the comprehensive "Bladder Cancer: Eight-Market Drug Forecast and Market Analysis" report, covering the 8 major markets (US, France, Germany, Italy, Spain, UK, Japan, China). Gain insights into disease epidemiology, 10-year patient-based forecasts, and market trends, as well as late-stage pipeline therapies set to drive market growth. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer: Eight-Market Drug Forecast and Market Analysis" report has been added to Highlights Report deliverables include a Pdf report and Excel-based forecast model Forecasts includes the 8MM Forecasts covers from 2021-2031 The analyst valued the bladder cancer market in the 8MM at $2.39 billion and expects the market to increase to $2.89 billion by 2031 Incyte, GSK and CTI BioPharma are expected to take market-leading position in 2031 A moderate level of unmet need will remain for most bladder cancer patient populations during the forecast period The late-stage pipeline in bladder cancer is robust and is likely to provide significant clinical benefit to many bladder cancer patient populations, with fierce competition expected This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for bladder cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from the analyst's World Markets Healthcare (WMH) and POLI Price Intelligence being a rare blood cancer, MF is a blockbuster market and is expected to grow from sales of $2.39 billion in 2021 to $2.89 billion in 2031, at a compound annual growth rate (CAGR) of 1.9%. Peak-year sales are set to be reached in 2027, driven by the approvals of several promising late-stage pipeline agents and the continued clinical dominance of Jakafi/Jakavi (ruxolitinib). In 2028, Jakafi/Jakavi is set to come off-patent in the US, which will greatly decrease its total market sales. However, the loss of total market sales will be somewhat recuperated in 2028 and beyond by the additional growth in market value of other pipeline Janus kinase (JAK) inhibitors and targeted therapies, with sales of these agents being driven by ameliorating critical unmet needs within the MF treatment markets across the 8MM will experience growth driven by common drivers: Approvals of late-stage pipeline agents, including novel JAK inhibitors and targeted therapies, which will partially meet critical unmet clinical needs Decreased reliance on generic immunomodulatory agents, androgens, and erythropoietin-stimulating agents Increased utilization of novel combination regimens with premium-priced agents Common barriers to market growth experienced across the 8MM primarily include a series of patent expiries: Patent expiry of Jakafi/Jakavi Patent expiry of Vonjo (pacritinib) Patent expiry of Inrebic (fedratinib) Key Highlights This report covers the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan and China). The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends. Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the severe asthma market. The base year of the sales forecast model is 2023, and the forecast period is 2023-2033. Scope Overview of bladder cancer, including epidemiology, symptoms, diagnosis, and disease management. Annualized bladder cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the bladder cancer therapeutics market. Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for bladder cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled. Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global bladder cancer therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bladder cancer therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships Key Topics Covered: Abbreviations Related Reports Executive Summary Disease Overview Overview of Bladder Cancer Bladder Cancer Market Strength, Weakness, Opportunity, and Threat Analysis Epidemiology Diagnosed Incident Cases Both Sexes Age-Specific Diagnosed Incident Cases Sex-Specific Diagnosed Incident Cases Diagnosed Incident Cases by Type, Sex, Age Diagnosed Incident Cases by Stage at Diagnosis Diagnosed Incident Cases by Tumor Stage at Diagnosis Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade Diagnosed Incident Cases of Stage of Bladder Cancer by Broad Classification Diagnosed Incident Cases of Stage of NMIBC by Risk Group Diagnosed Incident Cases of Bladder Cancer by Mutations and Biomarkers Five-Year Diagnosed Prevalent Cases of Bladder Cancer Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Tumor Stage Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Broad Classification Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Relapse or Recurrence Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Treatment Disease Management Treatment Guidelines Treatment Paradigm - First-Line Therapy in Non-Muscle Invasive Bladder Cancer Treatment Paradigm - First-Line Therapy in Muscle Invasive Bladder Cancer Treatment Paradigm - Locally Advanced/Metastatic Bladder Cancer KOL Insight on the Bladder Cancer Treatment Algorithm Unmet Needs and Opportunities Unmet Needs in Bladder Cancer Competitive Landscape Assessment Pipeline Drugs Overview Competitive Landscape Methodology Competitive Assessment - Intravesical Delivered Therapies for NMIBC Competitive Assessment - Gene Therapies for NMIBC Competitive Assessment - Antibody-Drug Conjugates Market Outlook Bladder Cancer Market Forecast Bladder Cancer Market Forecast by Class Bladder Cancer Market Drivers and Barriers Appendix Primary Research: KOL Information Sources Used and Not Used to Forecast Diagnosed Incident Cases Sources Used to Forecast Diagnosed Incident Cases by Stage at Diagnosis Sources Used to Forecast Diagnosed Incident Cases by Tumor Stage at Diagnosis Sources Used to Forecast Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade Sources Used to Forecast Diagnosed Incident and Five-Year Diagnosed Prevalent Cases by Broad Classification Sources Used to Forecast Diagnosed Incident Cases of NMIBC by Risk Group Sources Used to Forecast Diagnosed Incident Cases by Mutations and Biomarkers Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Relapse or Recurrence Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Treatment Sources and Methodology Epidemiological Forecast Insight Strengths and Limitations A selection of companies mentioned in this report includes, but is not limited to: AstraZeneca Merck Bristol-Myers Squibb Gilead Sciences LLC Roche Pfizer Immunomedics Inc Astellas Pharma Co Ltd Johnson & Johnson Daiichi Sankyo Co Ltd Ferring Pharmaceuticals Ltd ImmunityBio Inc BeiGene Ltd Bicycle Therapeutics Inc CG Oncology Inc Shanghai Miracogen Inc Fidia farmaceutici SpA Therlase Inc enGene Holdings Inc UroGen Pharma Inc For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
FTSE 100 LIVE: Stocks muted as London hosts US-China trade talks
The FTSE 100 (^FTSE) and European stocks were lacklustre on Monday morning as US and Chinese officials meet in London in a bid to making further progress in easing the trade war between the world's two largest economies. Both sides are sending senior representatives — the US delegation is being led by Treasury secretary Scott Bessent, commerce secretary Howard Lutnick and US trade representative Jamieson Greer, while vice premier He Lifeng leads China's team. A UK government spokesman said on Sunday: 'The next round of trade talks between the US and China will be held in the UK on Monday. We are a nation that champions free trade and have always been clear that a trade war is in nobody's interests, so we welcome these talks.' London's benchmark index (^FTSE) treading water in early trade Germany's DAX (^GDAXI) dipped 0.4% and the CAC (^FCHI) in Paris headed 0.2% into the red The pan-European STOXX 600 (^STOXX) was also trading near the flatline Wall Street is set for a positive start as S&P 500 futures (ES=F), Dow futures (YM=F) and Nasdaq futures (NQ=F) were all in the green. The pound was 0.3% higher against the US dollar (GBPUSD=X) at 1.3567. The value of the US greenback slipped against all major currencies ahead of the pivotal US-China trade talks Key companies reporting this week: TSMC, Adobe, Tesco, Bellway and Inditex Follow along for live updates throughout the day: Stocks in Asia rose overnight ahead of the second round of trade talks between Washington and Beijing, due in London later today. The Nikkei (^N225) rose 0.9% on the day in Tokyo, as the Japanese economy contracted by 0.2% in the first quarter, while the Hang Seng (^HSI) climbed 1.4% in Hong Kong. The Shanghai Composite ( was 0.4% up by the end of the session despite the government reporting that exports slowed in May. They grew 4.8% from a year earlier after a jump of more than 8% in April. Exports to the US fell almost 10% compared to the previous year. China also reported a 0.1% year-on-year fall in consumer prices in May, marking the fourth consecutive month of deflation. In South Korea, the Kospi (^KS11) added 1.6% on the day, while Australia's market was closed for a public holiday. On Friday, stocks gained ground on Wall Street following a better-than-expected report on the US job market. The gains were broad, with every sector in the S&P 500 (^GSPC) rising. This solidified a second consecutive winning week for the benchmark index, which has rallied back from a slump two months ago, within striking distance of its record high. The S&P 500 rose 1% to 6,000.36, the Dow Jones (^DJI) gained 1% to 42,762.87, while the Nasdaq (^IXIC) gained 1.2% to 19,529.95. Good morning, and welcome back to our markets live blog. As usual we will be taking a deep dive into what's moving markets and happening across the global economy. Here's a snapshot of what's on the agenda for today: 7am: Trading updates: Cordel Group, Synectics, Strip Tinning 3.30pm: US Wholesales Inventories 8pm: US Consumer CreditStocks in Asia rose overnight ahead of the second round of trade talks between Washington and Beijing, due in London later today. The Nikkei (^N225) rose 0.9% on the day in Tokyo, as the Japanese economy contracted by 0.2% in the first quarter, while the Hang Seng (^HSI) climbed 1.4% in Hong Kong. The Shanghai Composite ( was 0.4% up by the end of the session despite the government reporting that exports slowed in May. They grew 4.8% from a year earlier after a jump of more than 8% in April. Exports to the US fell almost 10% compared to the previous year. China also reported a 0.1% year-on-year fall in consumer prices in May, marking the fourth consecutive month of deflation. In South Korea, the Kospi (^KS11) added 1.6% on the day, while Australia's market was closed for a public holiday. On Friday, stocks gained ground on Wall Street following a better-than-expected report on the US job market. The gains were broad, with every sector in the S&P 500 (^GSPC) rising. This solidified a second consecutive winning week for the benchmark index, which has rallied back from a slump two months ago, within striking distance of its record high. The S&P 500 rose 1% to 6,000.36, the Dow Jones (^DJI) gained 1% to 42,762.87, while the Nasdaq (^IXIC) gained 1.2% to 19,529.95. Good morning, and welcome back to our markets live blog. As usual we will be taking a deep dive into what's moving markets and happening across the global economy. Here's a snapshot of what's on the agenda for today: 7am: Trading updates: Cordel Group, Synectics, Strip Tinning 3.30pm: US Wholesales Inventories 8pm: US Consumer Credit Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
